Mersana Therapeutics Balance Sheet Health
Financial Health criteria checks 5/6
Mersana Therapeutics has a total shareholder equity of $36.9M and total debt of $25.2M, which brings its debt-to-equity ratio to 68.4%. Its total assets and total liabilities are $226.1M and $189.2M respectively.
Key information
68.4%
Debt to equity ratio
US$25.23m
Debt
| Interest coverage ratio | n/a |
| Cash | US$209.08m |
| Equity | US$36.90m |
| Total liabilities | US$189.16m |
| Total assets | US$226.06m |
Recent financial health updates
Here's Why Mersana Therapeutics (NASDAQ:MRSN) Can Manage Its Debt Despite Losing Money
Oct 14
Is Mersana Therapeutics (NASDAQ:MRSN) A Risky Investment?
Jun 09Is Mersana Therapeutics (NASDAQ:MRSN) A Risky Investment?
Mar 23Recent updates
Mersana Therapeutics, Inc.'s (NASDAQ:MRSN) Shares Bounce 26% But Its Business Still Trails The Industry
Feb 27Mersana Therapeutics: A Bottom-Feeding Gamble Of A Stock
Jan 11Here's Why Mersana Therapeutics (NASDAQ:MRSN) Can Manage Its Debt Despite Losing Money
Oct 14Is Mersana Therapeutics (NASDAQ:MRSN) A Risky Investment?
Jun 09Mersana Therapeutics, Inc.'s (NASDAQ:MRSN) Intrinsic Value Is Potentially 22% Below Its Share Price
Feb 22Mersana gains as FDA grants fast track status for breast cancer drug
Sep 12Mersana Therapeutics: Savvy Partnering But Further Progress Is Needed
Aug 15Taking The Measure Of Mersana Therapeutics
Jan 10Mersana: ADC Developer With New INDs, Sufficient Cash, And XMT-1536 Progress
Jun 29It's Unlikely That The CEO Of Mersana Therapeutics, Inc. (NASDAQ:MRSN) Will See A Huge Pay Rise This Year
Jun 05Mersana Therapeutics EPS misses by $0.11, misses on revenue
May 10Is Mersana Therapeutics (NASDAQ:MRSN) A Risky Investment?
Mar 23Did Mersana Therapeutics, Inc. (NASDAQ:MRSN) Insiders Buy Up More Shares?
Jan 29
Bain Capital discloses 4.8% stake in Mersana Therapeutics
Jan 13Mersana: XMT-1536's Complications, New CMO, And 2H 2021's Critical Catalyst
Jan 11Mersana slumps as XMT-1536 shows lower response rate in ovarian cancer study
Jan 05Is Mersana Therapeutics, Inc. (NASDAQ:MRSN) Trading At A 42% Discount?
Dec 08Mersana Therapeutics EPS misses by $0.02
Nov 09Financial Position Analysis
Short Term Liabilities: MRSN's short term assets ($214.1M) exceed its short term liabilities ($63.6M).
Long Term Liabilities: MRSN's short term assets ($214.1M) exceed its long term liabilities ($125.5M).
Debt to Equity History and Analysis
Debt Level: MRSN has more cash than its total debt.
Reducing Debt: MRSN's debt to equity ratio has increased from 0% to 68.4% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: MRSN has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: MRSN has sufficient cash runway for 2.6 years if free cash flow continues to reduce at historical rates of 16.8% each year.